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Abstract
The aim of this study was to investigate the relationship between the promoter methylation in five cancer-associated
genes and clinicopathologic features for identification ofmolecularmarkers of tumormetastatic potential andhormone
therapy response efficiency in breast cancer. Themethylation levels in paraffin-embedded tumor tissues, plasma, and
blood cells from 151 sporadic breast cancer patients and blood samples of 50 controls were evaluated by quantitative
multiplexmethylation-specific polymerase chain reaction.DNAmethylationofRAS-associationdomain familymember 1
(RASSF1A), estrogen receptor 1 (ESR1), cadherin 1, type 1, E-cadherin (CDH1), TIMP metallopeptidase inhibitor 3
(TIMP3) and spleen tyrosine kinase (SYK) genes was detected in the tumors of 124, 19, 15, 15, and 6 patients with
mean levels of 48.45%, 3.81%, 2.36%, 27.55%, and 10.81%, respectively. Plasma samples exhibited methylation
in the same genes in 25, 10, 15, 17, and 3 patients with levels of 22.54%, 17.20%, 22.87%, 31.93%, and 27.42%,
respectively. Cumulative methylation results confirmed different spectra in tumor and plasma samples. Simultaneous
methylation in tumors and plasma were shown in less than 17% of patients. RASSF1A methylation levels in tumor
samples statistically differ according to tumor size (P = .029), estrogen receptor (ER) and progesterone receptor
(PR) status (P= .000 and P= .004), and immunohistochemical subtype (P= .000). Moreover, the positive correlation
was found between RASSF1A methylation levels and percentage of cancer cells expressing ER and PR. The direct
relationship between RASSF1A promoter methylation and expression of ER could aid the prognosis of hormonal
therapy response.
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Introduction
Breast cancer is the most common cancer in women worldwide.
According to data published by the International Agency for Research
on Cancer, in 2008, 1,383,000 breast cancer patients were newly
diagnosed and 458,000 breast cancer–related deaths occurred [1].
More than 25% of breast cancer patients develop metastatic disease that
is mostly incurable and for which there are only palliative therapeutic
options [2]. Clinicopathologic characteristics such as tumor size, lymph
node (LN) status, invasion of vessels, and hormone receptor status
play important roles in metastasis risk [3]. However, the results of a
recent multicenter study found differences in clinicopathologic fea-
tures between patients with and without primary metastases, and for
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metastasis risk, the lobular histology and luminal B positivity in T1 pri-
mary metastatic breast cancer were determined [2].
Similar to other cancer types, breast tumorigenesis is characterized
by the progressive accumulation of genetic and epigenetic changes in
many genes that regulate cell proliferation and differentiation. There-
fore, molecular characterization of tumor tissues allows determina-
tion of novel cancer markers including those predicting metastatic
potential and therapy response.
Epigenetic abnormalities in neoplastic cells, such as hypermethyla-
tion and hypomethylation of DNA, altered patterns of histone modi-
fication, and remodeled chromatin structure, result in the modified
expression of many essential genes. A well-categorized epigenetic
change is hypermethylation of tumor-suppressor promoters that led
to inappropriate transcription silencing of these genes [4]. The tumor
suppressor gene RAS-association domain family member 1 (RASSF1A)
encodes a member of the group of RAS effectors that regulates cell
proliferation, apoptosis, and microtubule stability. Hypermethylation
of RASSF1A was found in a substantial percentage of various primary
tumors [5]. Epigenetic inhibition of RASSF1A is considered to be an
early cancer biomarker; however, this phenomenon is extended from
primary to metastatic tumors during tumor progression [6]. Moreover,
in invasive breast cancers, significantly higher RASSF1A methylation
levels were shown compared with in situ carcinomas [7]. These results
indicate the possible association of RASSF1A silencing with metastasis.
Other studies reported higher frequencies of methylation in RASSF1A
alone or in combination withHIN-1 in estrogen receptor (ER)–positive
cases compared with ER-negative cases [8,9]. Moreover, a recent
in vitro study revealed that RASSF1A inhibits ERα expression and
function [product of estrogen receptor 1 (ESR1) gene]; thereby, it plays
a key role in suppressing transformation of mammary epithelial cells
and ERα-positive breast cancer initiation [10]. In addition to the
potential RASSF1A-mediated epigenetic regulation of ESR1, mild or
moderate DNA methylation of the ESR1 promoter alone was observed
in breast tumorigenesis, indicating the possible influence of epigenetic
processes on hormonal therapy response [11,12]. In tumorigenesis,
there are numerous changes in the cadherin-catenin adhesion com-
plexes, including the cell adhesion protein E-cadherin encoded by
cadherin 1, type 1, E-cadherin (CDH1). In primary breast cancer, the
heterogeneous loss of E-cadherin expression corresponding with vari-
able patterns of promoter methylation was observed in the early stages
before cell invasion [13]. CDH1 hypermethylation with loss of protein
expression was found in both ductal and lobular breast carcinomas;
however, no significant correlation was observed between E-cadherin
expression and the CDH1 promoter methylation profile [14]. The
tissue inhibitors of metalloproteinase (TIMPs) prevent degradation of
the extracellular matrix by the metalloproteinases. TIMP metallopepti-
dase inhibitor 3 (TIMP3) is a matrix-bound protein regulating matrix
composition that affects tumor growth, angiogenesis, invasion, and
metastasis. TIMP3 promoter methylation was observed in 21% to
27% of breast cancer patients and in invasive ductal carcinomas that
were associated with high tumor grading and LN metastasis [15,16].
The spleen tyrosine kinase (SYK) is an intracellular receptor protein
kinase involved in cell proliferation, differentiation, and phagocytosis
and plays a suppressive function in breast cancer progression and
metastasis [17]. The frequencies of SYK promoter hypermethylation
at different stages of breast cancer indicate its occurrence shortly before
the development of the invasion phenotype [18]. The objective of
the present study was to determine the association of the promoter
methylation profiles of five genes related to invasion and metastasis
with breast cancer clinicopathologic features to identify useful molec-
ular markers indicating the metastatic potential of tumors and patient
response to hormonal therapy.
Materials and Methods
Patients
A total of 151 paraffin-embedded tumor tissue samples and
matched 151 peripheral blood samples from nonfamilial breast cancer
patients and blood samples of 50 healthy controls were obtained from
the Department of Pathology and Department of Senology at hospitals
in Bratislava, Slovakia. This study was approved by Ethics Committee
of the University Hospital in Bratislava, and written informed consent
was obtained from all patients and controls. Relevant clinical and
pathologic data were retrieved from the patients’ clinical records, and
tumors were characterized according to the primary tumor, regional
lymph nodes, distant metastasis (TNM) classification. The age of pa-
tients ranged from 23 to 91 years (mean, 61.2 ± 10.8 years) at the time
of breast cancer diagnosis. Typing was performed according to the cur-
rent World Health Organization (WHO) classification for breast neo-
plasms (Table 1). No preoperative radiotherapy or chemotherapy had
been performed in any of the cases. Controls included 25 individuals of
<50 years and 25 individuals of >50 years who had no signs and symp-
toms of cancer or other serious diseases.
DNA Extraction and Sodium Bisulfite Modification
Blood samples of patients and controls were collected in EDTA-treated
tubes and centrifuged at 1000g for 10 minutes at room temperature
within 2 hours of venepuncture. Then, supernatants were collected
and centrifuged at 1000g for 10minutes at room temperature to prevent
cellular DNA contamination. Plasma samples were stored at −70°C un-
til further processing. Cell-free DNA from plasma samples was isolated
using a QIAamp DSP Virus Kit (Qiagen, Hilden, Germany), DNA
from paraffin-embedded tumor tissues was isolated by the MagneSil
Genomic, Fixed Tissue System (Promega, Madison, WI), and genomic
DNA from peripheral blood was obtained using a FlexiGene DNA Kit
(Qiagen) according to the manual instructions. DNA concentrations
were measured using a NanoDrop 1000 spectrophotometer (Thermo
Fisher Scientific, Bremen, Germany). Tumor DNA (2 μg), cell-free
DNA (2 μg), and genomic DNA (1 μg) were modified by sodium
bisulfite treatment according to the protocols of the EpiTect Bisulfite
Kit (Qiagen) and CpGenome DNA Modification Kit (Chemicon,
Billerica, MA), respectively. DNA was stored at −18°C until use.
Quantitative Multiplex Methylation-Specific Polymerase
Chain Reaction Analysis
For quantitative evaluation of promoter methylation, the two-color
modification of quantitative multiplex methylation-specific polymerase
chain reaction (QM-MSP) technology was used [19]. QM-MSP was
performed in two sequential polymerase chain reaction (PCR) reac-
tions. In the first step, co-amplification of three and two gene loci
(RASSF1A, CDH1, SYK and ESR1, TIMP3) was performed using
three and two pairs of methylation-independent external primers, re-
spectively. Multiplex PCRs were performed in 30-μl volumes contain-
ing 30 to 60 ng of modified DNA, 15 μl of 2× QIAGEN Multiplex
PCR Master Mix (Qiagen), and aliquots of six/four primers at a final
concentration of 0.2 μM. PCR conditions were 95°C for 15 minutes,
35 cycles at 94°C for 30 seconds, 62/56°C for 60 seconds, hybridiza-
tion at 72°C for 90 seconds, and final extension at 72°C for 10minutes.
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In the second step (quantitative real-time PCR), 1 μl of the first re-
action PCR product was used at a dilution of up to 1:102 in a duplex
reaction with both pairs of primers and specific TaqMan probes for
methylated and unmethylated DNA substrates for each gene. PCRs
were performed in 15-μl volumes containing 7.5 μl of Maxima Probe
qPCR Master Mix (2×; Fermentas, Amherst, NY), methylation- and
unmethylation-specific primers for RASSF1A, ESR1, CDH1, TIMP3,
or SYK gene at a final concentration of 0.3 μM, and methylation- and
unmethylation-specific TaqMan probes at concentrations ranging
from 0.1 to 0.27 μM. The reaction conditions were 50°C for 2 min-
utes, 95°C for 10 minutes, followed by 35 cycles at 95°C for 15 seconds
and 60°C for 30 to 90 seconds with final extension at 72°C for 30 sec-
onds. For quantitative PCR, a CFX96TM Real-Time PCR System
(Bio-Rad, Hercules, CA) was used. Standard curve establishment and
evaluation of quantitative analysis of DNAmethylation were performed
as previously described [20]. The relative amount of methylation (%)
was calculated in each sample according to the formula [M/(U +M)] ×
100. Concentrations of methylated (M) and unmethylated (U ) por-
tions were determined from simultaneously amplified standard curves
for each gene. Methylation levels up to 0.5% were considered to be
the background of this sensitive quantitative method. The cumulative
methylation index (CMI) was calculated as the sum of percentage meth-
ylation for all evaluated genes. For all five genes, CMI of 500 was the
maximum value of methylation. Primers and TaqMan probes are
summarized in the supplementary material (Table W1) [21].
Statistical Analysis
For statistical analyses, SPSS statistics 15.0 was applied, with P < .05
regarded as statistically significant. Normally distributed data were
tested by Pearson correlations, Student’s t tests, or analysis of variance
with Bonferroni or Tamhane tests for multiple comparisons, depend-
ing on homogeneity of variance. For non-normally distributed data,
Spearman correlations, nonparametric Mann-Whitney U or Kruskal-
Wallis H tests were used. Normality of distribution was assessed by
Table 1. RASSF1A Methylation Levels in Different Clinical and Histopathologic Categories in Breast Cancer Patients.
N RASSF1A Methylation in Tumor Samples RASSF1A Methylation in Plasma Samples
Mean Median P Value Mean Median P Value
151
Age .773 .669
≤50 17 37.9 44.4 1.8 0
>50 134 40.0 40.5 4.0 0
Histologic type .864 .660
DIC 131 40.1 40.6 3.8 0
LIC 10 40.1 49.1 5.2 0
Others 10 35.1 32.5 1.2 0
Tumor size .029 .643
≤20 90 41.9 42.6 4.1 0
>20 ≤ 50 47 32.1 31.5 3.9 0
>50 4 64.7 64.2 0 0
Histologic grading .668 .102
1 36 40.6 43.2 2.5 0
2 75 41.3 42.3 5.1 0
3 38 36.3 35.8 2.4 0
LN status .718 .297
0 86 42.2 43.2 3.7 0
1 36 36.5 36.8 2.2 0
2 11 36.1 40.4 13.4 0
3 6 43.1 49.6 0 0
TNM staging .066 .271
I 80 43.4 43.2 4.3 0
II 50 31.2 28.8 1.5 0
III 8 46.7 56.9 15.8 0
IV 1 65.9 65.9 0 0
ER status .000 .266
Negative 21 18.0 3.7 2.1 0
Positive 129 43.6 44.4 4.0 0
PR status .004 .863
Negative 33 27.4 22.4 5.1 0
Positive 117 43.5 44.4 3.4 0
HER2 expression .069 .419
Negative 128 38.2 39.3 3.3 0
Positive 22 50.8 43.8 6.7 0
IHC subtypes .000 .252
ER+/PR+ HER2− 114 42.2 44.2 3.3 0
ER+/PR+ HER2+ 16 51.0 46.2 9.2 0
ER− PR− HER2+ 7 43.1 42.3 0 0
ER− PR− HER2− 13 5.8 0 3.4 0
DIC indicates ductal invasive carcinomas; LIC, lobular invasive carcinomas; Others, tubular, micropapillar invasive, cribriform invasive, or mucinous breast carcinomas; LN status, lymph node status;
ER status, estrogen receptor status; PR status, progesterone receptor status; IHC subtypes, immunohistochemical subtypes.
P < .05 was regarded as statistically significant (in bold). LN status was categorized according to the number of cancer cell–positive nodes as 0, 1, 2, and 3 with none, 1 to 3, 4 to 10, and >10 of positive
LNs, respectively. ER or PR status was considered as positive in cases with ≥1% of positively responding cells. HER2 expression was regarded as positive, if the intensity of IHC reaction was 3+ in 30%
of tumor cells or with fluorescence in situ hybridization proven HER2 gene amplification in cases with ambiguous IHC positive at 2+ intensity reaction. According to ER, PR, and HER2 expression, four
IHC subtypes were recognized, luminal A and B (ER+ and/or PR+ HER− and ER+ and/or PR+ HER2+), HER2 overexpression positive (ER− PR− HER2+), and triple negative (ER− PR− HER2−).
Tumor sizes are shown in millimeters.
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Kolmogorov-Smirnoff tests. All tests were two-tailed. Categorical data
were tested by Chi square.
Results
DNA Methylation in Tumor and Plasma Samples
Quantitative analyses of DNA methylation were performed in
paraffin-embedded tumor tissues, blood cells, and plasma samples
from 151 breast cancer patients. Of these, 129 patients (85.4%) dem-
onstrated different levels of methylation in at least one of the evaluated
promoters in their tumors: in 124, 19, 15, 15, and 6 patients, mean
methylation levels of 48.45%, 3.81%, 2.36%, 27.55%, and 10.81%
were found in RASSF1A, ESR1,CDH1, TIMP3, and SYK, respectively.
In plasma samples, RASSF1A methylation was observed at a markedly
lower frequency of 22.54% in 25 patients. ESR1, CDH1, TIMP3, and
SYKwere methylated in 10, 15, 17, and 3 patients at 17.20%, 22.87%,
31.93%, and 27.42%, respectively. DNA methylation levels of five
evaluated genes in tumor and plasma samples are graphically depicted
in Figure 1. Simultaneously methylated promoters in both tumor and
plasma samples were found in 25, 1, 2, 4, and 1 patients in RASSF1A,
ESR1, CDH1, TIMP3, and SYK genes, respectively (Table 2). Low
levels of TIMP3 methylation (0.53–5.15%) were detected in the
genomic DNA of four breast cancer patients. Of 50 healthy controls,
methylation levels of >0.5% in the CDH1 promoter was observed in
the genomic DNA of one person alone. However, in the control plasma
samples, rare methylation events in CDH1 were found in one person
(1.67%), TIMP3 in two (16.52% and 20.40%), and ESR1 in two
(7.12% and 16.72%). The number of methylated genes was deter-
mined in individual patients. Of 129 patients with any methylation
in tumor tissues, 91, 30, and 7 samples were methylated in one,
two, and three evaluated genes, respectively. One patient manifested
promoter methylation in all five genes; however, the CMI was only
77.14. Of 49 patients with methylation in plasma, 37, 7, and 5 samples
were methylated in one, two, and three genes, respectively (Figure 2).
The cumulative methylation levels for the five evaluated genes were sig-
nificantly higher in the tumors and plasma than in the genomic DNA of
the same patients. In the methylation-positive tumor and plasma sam-
ples, the mean CMIs were 50.52 and 32.96, respectively, compared with
no methylation in genomic DNA except for four patients with TIMP3
methylation. However, a similar range of cumulative methylation in
tumor and plasmaDNA (0.74–156.57 and 0.51–151.62) was observed.
In the majority of tumors, the substantial portion of CMI was repre-
sented by RASSF1A methylation when compared with more frequent
methylation of other genes in plasma samples.
RASSF1A Methylation Levels and
Clinicopathologic Categories
Statistical analysis of the correlation between methylation levels and
clinicopathologic features of 151 breast cancer patients was performed
for the highly and frequently methylated RASSF1A gene. The evalu-
ated categories were age, histologic type, tumor size, histologic grading,
LN status, TNM staging, ER status, progesterone receptor (PR) status,
human epidermal growth factor receptor 2 (HER2) expression, and
immunohistochemical (IHC) subtypes. In plasma samples, RASSF1A
methylation ranged from 0% to 15.8%, with no significant differences
between the subgroups of each clinicopathologic category. The tumor
samples of these patients exhibited visibly higher levels of RASSF1A
Table 2. Frequencies of Breast Cancer Patients with DNA Methylation in Tumor and Plasma Samples.
Evaluated Genes Promoter Methylation in Tumor, N (%) Promoter Methylation in Plasma, N (%) Promoter Methylation in Both Tumor and Plasma, N (%)
RASSF1A 124 (82.1) 25 (16.6) 25 (16.6)
ESR1 19 (12.8) 10 (6.7) 1 (0.7)
CDH1 15 (9.9) 15 (10) 2 (1.3)
TIMP3 15 (9.9) 17 (11.5) 4 (2.7)
SYK 6 (4) 3 (2) 1 (0.7)
Figure 1. Methylation levels of five genes evaluated in tumor and plasma samples of breast cancer patients.
300 RASSF1A Methylation and ER Expression Kajabova et al. Translational Oncology Vol. 6, No. 3, 2013
methylation, and statistically significant differences were observed
between patients with various tumor size (P = .029), ER-negative
and ER-positive status (P = .000), PR-negative and PR-positive status
(P = .004), and different IHC subtypes (P = .000; Table 1 and Figure 3).
Moreover, there was a positive correlation between RASSF1Amethyla-
tion levels and the percentage of cancer cells with ER (r = 0.251,
P = .002) or PR expression (r = 0.200, P = .014).
Discussion
Quantification of DNA methylation levels in cancer-associated genes
contributes to the more complex molecular characterization of tumors
required for the development of new diagnostic and therapeutic strat-
egies for cancer patients. High methodical diversity of DNA methyla-
tion status evaluation was found in the current literature; therefore, we
compared our results with these studies using quantitative methods
based on real-time technology. In tumor samples, we found RASSF1A
methylation in 82.1% of evaluated breast cancer patients, with a mean
level of 48.45% in methylated cases. In other studies, analogous fre-
quencies (68% and 82.5%) but lower means of methylation levels
(18.5 ± 4.7% and more than 10%) were found in the majority of
patients [21,22]. Similar to our results, previous studies recorded
low incidences of ESR1 methylation in breast cancers and weak cor-
relation with low ERα expression levels, indicating a sporadic role
of DNA methylation in ER silencing [11,23]. In the present study,
9.9% of patients exhibited CDH1 promoter methylation levels of
up to 14.56% in tumor tissues, similar to other groups of patients
where low levels of CDH1 methylation frequencies from 5.8% to
22.5% were observed [20,22,24]. Variable TIMP3 methylation levels
of 3% to 42% were identified in the samples of nine patients [25], in
accordance with our findings; however, to our knowledge, quantitative
evaluation of SYK methylation has not yet been performed. Compar-
ison of studies in European, American, and Saudi Arabian females re-
vealed that the highest methylation levels were in RASSF1A similar
to our study, confirming the important role of RASSF1A epigenetic
silencing in breast cancer regardless of ethnicity [21,23,24].
Circulating cell-free DNA from plasma, serum, or other body fluids
seems to be an appropriate biologic material for qualitative or quanti-
tative testing of tumor-specific molecular alterations including DNA
methylation. The serum of patients with invasive ductal carcinomas
showed significantly higher RASSF1A methylation frequencies com-
pared with control persons [26], as in our study. We found significantly
lower frequencies of RASSF1Amethylation in plasma samples (16.6%)
than in tumors (82.1%); however, all 25 patients with positive find-
ings in plasma had simultaneous methylation in their tumor samples.
For ESR1, CDH1, TIMP3, and SYK, rare incidences were observed
in both tumor and plasma samples. ESR1 was evaluated in the serum
of healthy controls and disease-free breast cancer and metastatic breast
Figure 2. Cumulative DNA methylation levels in breast cancer patients. The results from tumor tissues of 129 patients (A) and plasma
samples of 49 patients (B) are shown. The CMI is the sum of percentage methylation for five evaluated genes.
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cancer patients and revealed no differences in the low levels of ESR1
methylation between these three groups [27]. Our results oppose the
above-mentioned hypothesis describing the possible influence of ESR1
epigenetic silencing alone in the strategy of breast cancer therapy. Many
researchers have focused on the identification of useful sets of methyl-
ated genes to improve diagnosis, prognosis, or therapeutic strategy;
therefore, CMI appears to be a useful parameter. The high incidence
of RASSF1Amethylation in CMI shows the value of this silenced gene
in tumor development in our patients. However, in 49 plasma sam-
ples, we found a different spectrum in CMI, with visibly higher occur-
rences of TIMP3 and CDH1 methylation. These results indicate that
cell-free DNA could be derived from a degraded cell subpopulation,
which is active in invasive and metastatic processes, for example, circu-
lating tumor cells, rather than from products of apoptosis and necrosis
in heterogeneous tumor masses [28]; therefore, these DNA samples
could be used for metastatic potential testing. However, after the critical
evaluation of methodical diversity, variability of results, and limited
diagnostic sensitivity and specificity of cell-free DNA alterations in
many published studies, we agree that clinical utilization of such DNA
requires further studies to assess sample collection, processing, analysis,
and measurement of results [29].
In our previous study, no relationship between tumor size and
RASSF1A methylation levels was observed [20], but in the presented
group of patients we found significantly higher levels in four cases with
breast tumors larger than 50 mm, three of which were at an advanced
stage of disease. The accumulation of DNA methylation changes could
be associated with aggressive phenotype rather than larger size of tumor,
because small cancers can also invade and metastasize as a result of
higher numbers of molecular changes compared with early-stage
cancer. Most importantly, we found a relationship between RASSF1A
methylation levels and expression of hormonal receptors. Previous
studies showed higher frequency of RASSF1A methylation in breast
cancers with ER+ and PR+ status than in ER− and PR− cases
[24,30]; however, we observed a positive correlation between RASSF1A
methylation levels in tumor tissues and number of cancer cells with
positive expression in both ER and PR. Analyses of RASSF1Amethyla-
tion in four different IHC subtypes showed very low levels in ER−
PR− HER2− but not in ER− PR− HER2+. Moreover, in cancers with
HER2 overexpression, higher but statistically insignificant differences
in methylation levels were observed compared with HER2-negative
cancers. These results indicate the possible influence of HER2 on
DNA methylation processes.
Figure 3. Distribution of RASSF1A methylation levels in four clinical and histopathologic categories of breast cancer patients. Box plots
show the significant differences in the subgroups of patients with different tumor sizes (A), negative and positive estrogen or progesterone
status (B and C), and different IHC subtypes (D). The length of the boxes is the interquartile range (IQR) that represents values between
the 75th and 25th percentiles. Values more than three IQRs from the end of a box are labeled as extreme (*). Values more than 1.5 IQRs
but less than 3 IQRs from the end of the box are labeled as outliers (O). The median is depicted by a horizontal line.
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In normal human breast epithelium, ERα expression is fairly consis-
tent over time, and women with ER overexpression in the normal
breast may have increased estrogen sensitivity that is associated with
higher breast cancer risk [31]. In previous case-control studies, the in-
cidence of breast epithelial cells expressing ER was higher in breast can-
cer cases than benign breast disease controls [32]; however, Woolcott
and colleagues did not confirm this strong association [33]. ER expres-
sion in luminal breast cancers varied from 1% to 100% of positively
stained cells, and even patients with 1% of ER-expressing tumor cells
experience some clinical benefit from endocrine therapies [34]. There-
fore, in addition to ER levels, ER dynamics could play an important
role in tumor behavior including therapy response. In a recent study,
a mouse model using patient-derived ER+ tumor xenografts was de-
veloped for the evaluation of intratumoral hormone and receptor
action. The researchers reported that analysis of the ER transcriptome
in selected tumors showed notable differences in the ER mechanism of
action and downstream-activated signaling networks, in addition to
identifying a small set of common estrogen-regulated genes. Mapping
of conserved and tumor-unique ER programs can contribute to the
development of more personalized therapeutic strategies [35]. Both
estrogen signaling and epigenetic modifications, in particular DNA
methylation, are involved in the regulation of gene expression in breast
cancers. Putnik and colleagues investigated the potential regulatory
cross talk between these two pathways in human MCF-7 breast cancer
cells. They identified approximately 140 genes that were influenced by
both 17β-estradiol and a demethylating agent 5-aza-20-deoxycytidine;
however, they did not show a direct molecular interplay of estrogen
mediators and epigenetic signaling at the promoters of regulated
genes [36]. Furthermore, in a recent study of the RASSF1A tumor-
suppressive function in MCF-7 cells, reconstitution of RASSF1A
expression decreased ERα levels, followed by reduced expression of
Id1 and the E2-responsive genes BCL-2 and C-MYC, up-regulation
of p21Cip1/Waf1 induction of cell-cycle arrest and senescence, and
inhibition of signaling pathways involved in breast epithelial cell trans-
formation. These findings indicate a central role of RASSF1A in sup-
pressing transformation of human breast epithelial cells in part through
ERα inhibition [10]. This hypothesis is supported by the present
study, because we observed a positive correlation between RASSF1A
methylation levels and percentage of ER- or PR-positively stained cells
in contrary to hormone receptor–negative cases with low levels of
methylation. In another study of heterogeneity of matched breast pri-
mary tumors and metastases, 3 of 10 evaluated patients exhibited no
RASSF1A methylation and a hormone-negative phenotype in both
types of tissues [37]. Previous work carried out in vitro is convinc-
ing; however, detailed studies of cancer-associated changes in the ER
mechanism of action in human tumors will enable association of the
“ER-dependent pathway patterns” with the effectiveness of hormonal
therapy and may help to develop new therapeutic molecules.
To summarize, in the present study, we observed high frequencies of
RASSF1A methylation and positive correlation of RASSF1A methyla-
tion levels with ER and PR expression in breast cancer patients. There-
fore, we speculate that the levels of RASSF1A methylation in ER+
breast cancer patients could be helpful in determining prognosis and
hormonal therapy response. Clinical utility of cell-free DNA isolated
from plasma for cancer-associated molecular characteristics testing,
namely, DNA methylation, is unsatisfactory because of its low de-
tection sensitivity. Furthermore, the specific methylation spectra in
plasma samples related to invasive and metastatic processes need to
be further evaluated in larger study cohorts.
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Table W1. Primers and TaqMan Probes.
Primer Name Oligonucleotide Sequence (5′–3′) Product Size (bp) Reference
RASSF1A F TTTAGTTTGGATTTTGGGGG 139 Present study
RASSF1A R CAACTCAATAAACTCAAACTCCC Present study
RASSF1A Met F GCGTTGAAGTCGGGGTTC 85 [21]
RASSF1A Met R CCCGATTAAACCCGTACTTCG Present study
RASSF1A Met R Probe FAM–ACAAACGCGAACCGAACGAAACCA–BHQ-1 [21]
RASSF1A Umet F GGTGTTGAAGTTGGGGTTTG 86 [21]
RASSF1A Umet R CCCAATTAAACCCATACTTCACT Present study
RASSF1A Umet R Probe HEX–CTAACAAACACAAACCAAACAAAACCA–BHQ-1 [21]
CDH1 F GGAATTGTAAAGTATTTGTGAGTTTG 169 Present study
CDH1 R AAATACCTACAACAACAACAACAAC Present study
CDH1 Met F AGTTCGTTTTAGTTCGGTTCG 98 Present study
CDH1 Met R GCCGAAAAACTACGACTCCA Present study
CDH1 Met F Probe FAM–TTCGTTCGGCGTTTTCGGTTAGT–BHQ-1 Present study
CDH1 Umet F AGTTTGTTTTAGTTTGGTTTGATT 98 Present study
CDH1 Umet R ACCAAAAAACTACAACTCCAAAA Present study
CDH1 Umet F Probe HEX–TTTGTTTGGTGTTTTTGGTTAGTTATG–BHQ-1 Present study
ESR1 F GGGAGATTAGTATTTAAAGTTGGAG 205 Present study
ESR1 R CCACCTAAAAAAAAAACACAACC Present study
ESR1 Met F CGGAGGGCGTTCGTTTT 115 Present study
ESR1 Met R GCATATCCCGCCGACACG Present study
ESR1 Met F Probe FAM–TTCGTCGGGTCGTTCGGTTTTATCG–BHQ-1 Present study
ESR1 Umet F GGTGGAGGGTGTTTGTTTT 118 Present study
ESR1 Umet R CACATATCCCACCAACACAC Present study
ESR1 Umet F Probe HEX–TTTGTTGGGTTGTTTGGTTTTATTGGA–BHQ-1 Present study
TIMP3 F GGAGGTTAAGGTTGTTT 175 Present study
TIMP3 R CAAACTCCAACTACCCAAAAAC Present study
TIMP3 Met F AGGTTAAGGTTGTTTCGTACGGTTC 122 Present study
TIMP3 Met R CGCTACTACCGCCGCTACC Present study
TIMP3 Met F Probe FAM–CGGGCGAGCGAGTTCGGGT–BHQ-1 Present study
TIMP3 Umet F TAAGGTTGTTTTGTATGGTTTG 126 Present study
TIMP3 Umet R ATCATTACCACTACTACCACCACTAC Present study
TIMP3 Umet F Probe HEX–TGGGTGAGTGAGTTTGGGTTGTAGT–BHQ-1 Present study
SYK F GGAAGTTGTTTAAAATGAGGAAGA 180 Present study
SYK R TAACCTCCTCTCCTTACCAAA Present study
SYK Met F CGGCGGTTGGAGAGC 82 Present study
SYK Met R GCGACCACACCTACCTACG Present study
SYK Met F Probe FAM–TTCGCGTTGCGTTCGTTTTCGT–BHQ-1 Present study
SYK Umet F GGTGGTGGTTGGAGAGTG 87 Present study
SYK Umet R AACACAACCACACCTACCTACA Present study
SYK Umet F Probe HEX–TGGTTTTGTGTTGTGTTTGTTTTTGTTT–BHQ-1 Present study
